Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3

Description

Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 participants who will experience either the active TLI or the placebo for 6 months.

Conditions

Alzheimer's Disease, Mild Cognitive Impairment

Talk to us

Study Overview

On this page

Study Details

Study overview

Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 participants who will experience either the active TLI or the placebo for 6 months.

Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 3

Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3

Condition
Alzheimer's Disease
Intervention / Treatment

-

Contacts and Locations

Menands

Icahn School of Medicine at Mount Sinai, Menands, New York, United States, 12204

New York

Icahn School of Medicine at Mount Sinai, New York, New York, United States, 10029

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of Alzheimer's disease or related dementia with a Montreal Cognitive Assessment score \<25
  • * Sleep disturbance with a Pittsburgh Sleep Quality Index score ≥5
  • * Extensive brain vascular disease, traumatic brain injury, multiple sclerosis, Parkinson's Disease
  • * Obstructing cataracts
  • * Severe macular degeneration
  • * Use of sleep medication
  • * Use of oral melatonin
  • * untreated moderate to severe sleep apnea
  • * Severe restless leg syndrome - Blindness

Ages Eligible for Study

55 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Icahn School of Medicine at Mount Sinai,

Mariana Figueiro, PhD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai

Study Record Dates

2027-01-31